Compare H2O America (HTO) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
H2O America vs Incyte Corporation — how do they compare? H2O America trades at $58.54 (market cap $2.43B), while Incyte Corporation trades at $112.77 (market cap $22.85B). The key difference: Incyte Corporation is far larger — about 9.4× H2O America's market cap, and H2O America pays a 3.03% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold H2O America for 40 Days and Incyte Corporation for 33 Days on average.
| HTO | INCY | |
|---|---|---|
Market Cap | $2.43B | $22.85B |
Volume | 593,883 | 1,927,029 |
Sector | Utilities | Health |
52-Week High | $65.43 | $129.93 |
52-Week Low | $44.44 | $83.80 |
Typical Hold Time | 40 Days | 33 Days |
Enterprise Value | $4.22B | $18.35B |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HTO trades at $58.70, up 1.24% with mixed technical signals showing bearish moving averages but bullish oscillators. The company maintains strong profitability with 12.91% net margins and recently completed the Quadvest acquisition through its Texas subsidiary. Analyst consensus remains strongly bullish with 83% buy ratings and a $66.50 price target, representing 13% upside potential from current levels.
The outlook appears favorable given the strategic acquisitions and Dividend King status, though execution risks from recent equity dilution and negative cash flow from investing activities warrant monitoring. The stock offers value with reasonable P/E of 20.45 and consistent earnings beats, supported by institutional accumulation including BlackRock's significant position.
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
